FUNDED PROJECTS FOLLOWING THE 2014 INTERNAL CALL
|WP1 – New immune markers and therapeutic targets for immunomodulating or depleting therapies|
|T1.4. A new anti-CMV strategy to prevent primary infection during HSCT|
|F.Haspot / I. Anegon|
|T1.5. Functional Contribution of MICA Polymorphic variants to Immune Responses in Organ Transplantation and in Cancer|
|N. Gervois / B. Charreau|
|T1.6. HO-1 and tolerance (HOT)|
|Anegon / JF. Fonteneau|
|WP2 – Innovative cellular immunotherapies|
|T4.3. Adoptive cell therapy for glioblastoma – characterization of tumor cell targets and analysis of their recognition by human t lymphocytes in vitro and in vivo|
|E. Scotet / C. Pecqueur|
|T5.1. Tracking of tumor-specific T cells|
|Y. Guilloux / E. Mortier|
|WP3 – Combined therapies|
|T7.3. Melanoma vaccination : coupling optimized long peptides to a viral protein that targets dendritic cells and favors cross-presentation|
|F. Lang / P. Jeannin|
To identify new immune markers and therapeutic targets for immunomodulating or depleting strategies , IGO will characterize new immune mechanisms regulating antitumor immunity and allograft rejection, and set up new animal models and immune monitoring methods to accelerate the obtention of preclinical and clinical proof ofefficacy.
To design cellular immunotherapies with enhanced efficacy, IGO will implement clinical grade protocols for sorting, in vitro expansion and functional differentiation of adoptively transferred immune cells, and design cell labeling protocols with enhanced sensitivity and reduced toxicity for better in vivo tracking of transferred cells.
Finally in order to develop new immunodepleting and immunomodulating strategies with broader indications and enhanced efficacy , IGO will evaluate
(i) new immune resistance pathways in relation to cell survival,
(ii) cross‐assess existing or new mmunotherapies in tumor, allotransplantation, or autoimmune indications, and
(iii) design innovative radioimmunotherapies or combination immunotherapies enhancing the immunodulating or depleting effect of therapeutic antibodies.